AstraZeneca's COVID-19 vaccine showed 79% efficacy against symptomatic disease and 100% efficacy against severe disease and hospitalization in a new, US-based clinical trial, the company said, Monday.
The findings from the new Phase 3 trial, which included more than 32,000 participants, may boost confidence in the vaccine, which was originally developed by the University of Oxford.
The trial showed that the vaccine was well-tolerated and identified no safety concerns, the company said. An independent committee "found no increased risk of thrombosis or events characterized by thrombosis among the 21,583 participants receiving at least one dose of the vaccine", according to AstraZeneca.
The new data came from a Phase 3 clinical trial conducted in the US, Chile, and Peru. AstraZeneca says it plans to submit the findings to a scientific journal for peer review.
For its part, Oxford said the findings add "to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom", according to press release from the University.
As part of the trial, more than 32,000 volunteers recruited across all ages received either two doses of the vaccine or a placebo vaccine at a four-week interval.
The Oxford-AstraZeneca vaccine become the subject of controversy earlier in the month when a number of European countries including Norway, France and Denmark decided to temporarily suspended its rollout due to reports of blood clotting in patients post-inoculation.